RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

ABSTRACT:

Objectives

Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and modified RECIST (mRECIST) are commonly used to assess tumour response. Which one is better to evaluate efficacy after molecular targeted therapies in hepatocellular carcinoma (HCC) patients is still controversial. A systemic review was performed to compare the objective response rate (ORR) and disease control rate (DCR) and a meta-analysis was conducted to compare the correlation between objective response and overall survival (OS).

Design

Systematic review and meta-analysis using the Grading of Recommendations Assessment, Development and Evaluation approach.

Data sources

EMBASE, PubMed, Web of Science and Cochrane Library were searched through 31 December 2021.

Eligibility criter

SUBMITTER: Yu H 

PROVIDER: S-EPMC9161105 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature